Drug Profile
Xanthoepocin
Latest Information Update: 25 Jun 2003
Price :
$50
*
At a glance
- Originator Ajinomoto
- Class Antibacterials
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-positive infections; Mycoses
Most Recent Events
- 13 Nov 2000 New profile
- 13 Nov 2000 Preclinical development for Gram-positive infections in Japan (Unknown route)
- 13 Nov 2000 Preclinical development for Mycoses in Japan (Unknown route)